Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study

Ida, Hanae; Honma, Yoshitaka; Hirano, Hidekazu; Shoji, Hirokazu; Iwasa, Satoru; Okita, Natsuko; Takashima, Atsuo; Kato, Ken; Fukuda, Takahiro; Boku, Narikazu

doi:10.1007/s10637-018-0669-7

Cited by 3 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies that evaluated the median PFS in patients on LAN treatment for the management of GEP or bronchial NETs are summarised in Supplementary File 1 (Table 1a, b) [4,5,[11][12][13][14][15][16][17][18][19][20][21]. The PFS reported in our study is in agreement with other publications [4,5,13,14,16,20,21].…”

Section: Discussionsupporting

confidence: 90%

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms

et al. 2019

View full text Add to dashboard Cite

Purpose The antiproliferative properties of lanreotide autogel (LAN) in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) were demonstrated in the CLARINET study. However, there is limited literature regarding factors that affect progression-free survival (PFS) in patients with GEP NENs treated with LAN. Methods We identified a total of 191 treatment-naive patients with advanced GEP NENs and positive SSTR uptake on imaging (Octreoscan or 68 Gallium DOTATATE Positron Emission Tomography [ 68 GaPET]) who received first-line LAN monotherapy, albeit at various starting doses (60, 90 or 120 mg/month). A group of 102 patients who initiated treatment at the standard dose of 120 mg/month were included in the study and further evaluated by univariate and multivariate analyses to identify predictors of PFS. Results The location of tumour primary was in the small bowel in 63 (62%), pancreas in 31 (30%) and colon/rectum in 8 patients (8%). The tumours were well-differentiated, and the majority were grade 1 (52%), or 2 (38%). About 60% of cases had progressive disease at the time of treatment initiation. Most patients with available pretreatment nuclear medicine imaging (Octreoscan or 68 Ga PET) had a Krenning score of 3 (44%) or 4 (50%). The median PFS for the entire cohort was 19 months (95% CI 12, 26 months). The univariate analysis demonstrated that grade 2 tumours, progressive disease at baseline and metastatic liver disease were associated with a significantly shorter PFS, while other evaluated variables did not affect PFS at a statistically significant level. However, at multivariate analysis only the tumour grade remained statistically significant. Conclusions The current study showed that, of many evaluated variables, only the tumour grade was predictive of PFS duration and this should be considered during patient selection for treatment.

show abstract

Section: Discussionsupporting

confidence: 90%

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, SAA as first-line therapy exhibited an objective response rate (ORR) of no more than 10%. 11 In addition, a study suggested that everolimus, an inhibitor of mammalian target of rapamycin (mTOR), is an effective and promising treatment for thymic NEN. 12 Of note, Ma et al revealed that dihydroorotate dehydrogenase (DHODH) is target for MEN1-mutated tumor cells, and leflunomide, an inhibitor of DHODH, can efficiently impede the growth of MEN1-mutated tumors.…”

Section: Discussionmentioning

confidence: 99%

“…National Comprehensive Cancer Network (NCCN) guidelines recommend that octreotide can be used as first‐line therapy for patients with local unresectable or distant metastases lesions. However, SAA as first‐line therapy exhibited an objective response rate (ORR) of no more than 10% 11 . In addition, a study suggested that everolimus, an inhibitor of mammalian target of rapamycin (mTOR), is an effective and promising treatment for thymic NEN 12 .…”

Section: Discussionmentioning

confidence: 99%

Successful management of a multiple endocrine neoplasia type 1‐associated thymic neuroendocrine neoplasms with acute chest pain as initial symptom: A rare case report

Li,

Gu,

Zhao

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageAcute chest pain can be the first manifestation of multiple endocrine neoplasia type 1(MEN1)‐associated thymic neuroendocrine neoplasms (NEN). Comprehensive treatment may be an effective strategy for MEN1‐associated NEN.AbstractMultiple endocrine neoplasia type 1(MEN1)‐associated thymic neuroendocrine neoplasms (NEN) is caused by the mutation of tumor suppressor MEN1 gene. Patients with MEN1‐associated NEN initially presenting with acute chest pain are very rare. In the manuscript, we reported a case of a 45‐year‐old man who developed MEN1‐associated NEN with acute chest pain as initial symptom. Thoracoscopic thymotomy was performed and thymic NEN was successfully removed. Genetic test showed a germline mutation of MEN1 gene in this patient. Immunohistochemical staining exhibited Syn(+), CgA(+), INSM1(+), CD56(+) and Ki67‐positive cells (2%) in MEN1‐associated NEN. Further evaluation unveiled MEN1‐associated benign tumors including digestive NEN and pituitary gland adenoma. The 99mTc‐HYNIC‐TOC scintigraphy showed that focally increased radioactivity in the mid‐upper abdomen. This patient was administered with 50Gy/25F of radiation dose to treat the postoperative lesions. Subsequently, sandostatin LAR (30 mg per week) was used as systemic therapy. He had no recurrence or metastasis for 6‐month follow‐up. Thus, acute chest pain can be the first manifestation of MEN1‐associated NEN, and comprehensive treatment including surgery, radiation and systemic treatment may be an effective strategy for MEN1‐associated NEN.

show abstract

“…These results are not consistent with the recent report; a study in Japan showed that median PFS on somatostatin analogs in patients with foregut/hindgut NETs was similar to that with midgut NETs. 19 A clinical trial of lanreotide is currently ongoing in South Korea in patients with hindgut NETs and this may help clarify the efficacy of lanreotide for hindgut NETs; 20 however, additional research into the response of patients with hindgut NETs is also warranted.…”

Section: Discussionmentioning

confidence: 99%

Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study

Ito

Fujimori

Honma

et al. 2020

Asia-Pac J Clncl Oncology

Self Cite

View full text Add to dashboard Cite

Aim:The aim of this study was to describe the long-term safety and efficacy of lanreotide in Japanese patients with neuroendocrine tumors. Methods: The final analyses of a 48-week open-label phase II study (n = 32) and its extension study (n = 17) were conducted. Patients received 4-weekly subcutaneous injections of lanreotide autogel 120 mg. Safety was evaluated by adverse events. Efficacy endpoints included tumor response by RECIST and change in tumor size. Post hoc analyses including tumor growth rate were performed. Results:The median (range) of lanreotide exposure in the safety analysis set (n = 17) and efficacy analysis set (n = 28) were 151.4 (52-181) and 52.7 (12-181) weeks, respectively. Sixteen patients developed adverse drug reaction; of these, upper abdominal pain and urticaria were not reported before 48 weeks. No patient discontinued lanreotide or died from an adverse event.Two serious events of bile duct stones in one patient were drug-related. Partial response was observed in 2 patients (7.1%; at 60 and 108 weeks), stable disease in 20 (71.4%) and progressive disease in 6 (21.4%). The mean of the greatest change from baseline in the sum of diameters of target lesions was −5.5%. The mean (standard deviation) tumor growth rate beforeThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

show abstract

Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study

Cited by 3 publications

References 14 publications

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms

Successful management of a multiple endocrine neoplasia type 1‐associated thymic neuroendocrine neoplasms with acute chest pain as initial symptom: A rare case report

Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study

Contact Info

Product

Resources

About